'435 patent stands partially valid while '127 all invalidated | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

  • Important Upgrade Notice: 


    At 9 pm Central, Sunday 2/16/2020, we launched the following tools as Phase One of our Premium Plus service (full service package still under development): 

    1) Customizable Scrolling Ticker
    2) Portfolio Manager
    3) Stock-specific News & Trading Email Alert Notifications

    These products are immediately available to Precious Metal & Gemstone Patrons. 

    To watch a tutorial on the "regular" site, click here. On "premium," click here


ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34753 of 34763  at  1/7/2020 11:21:01 PM  by

liuyiiv


 In response to msg 34752 by  liuyiiv
view thread

Re: '435 patent stands partially valid while '127 all invalidated

valid claims:
 
7. The nucleic acid-lipid particle of claim 5, wherein the phospholipid comprises from 3 mol % to 15 mol % of the total lipid present in the particle.
8. The nucleic acid-lipid particle of claim 5, wherein the cholesterol or derivative thereof comprises from 30 mol % to 40 mol % of the total lipid present in the particle.
10. The nucleic acid-lipid particle of claim 9, wherein the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof.
11. The nucleic acid-lipid particle of claim 10, wherein the PEG-DAA conjugate comprises a PEG-dimyristyloxypropyl (PEG-DMA) conjugate, a PEG-distearyloxypropyl (PEG-DSA) conjugate, or a mixture thereof.
13. The nucleic acid-lipid particle of claim 1, wherein the nucleic acid is fully encapsulated in the nucleic acid-lipid particle.
16. A method for the in vivo delivery of a nucleic acid, the method comprising:
administering to a mammalian subject a nucleic acid-lipid particle of claim 1.
17. A method for treating a disease or disorder in a mammalian subject in need thereof, the method comprising:
administering to the mammalian subject a therapeutically effective amount of a nucleic acid-lipid particle of claim 1.
18. The method of claim 17, wherein the disease or disorder is a viral infection.
19. The method of claim 17, wherein the disease or disorder is a liver disease or disorder.
20. The method of claim 17, wherein the disease or disorder is cancer.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 206
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...